Quoin Pharmaceuticals Reports Promising Initial Results for QRX003 in Pediatric Peeling Skin Syndrome Study

May 14, 2025

DENVER, Colo., May 14, 2025 (247marketnews.com)- Quoin Pharmaceuticals (NASDAQ:QNRX) reported encouraging initial data from its ongoing Pediatric Peeling Skin Syndrome clinical study.

Dr. Michael Myers, Quoin’s CEO, stated, “We are very pleased to announce such positive initial data across a number of clinical endpoints for the pediatric subject in this study, which we believe may be the first formal clinical study for this disease. The two grade improvement, which is accepted as being clinically meaningful in both the Investigator’s Global Assessment (IGA) (severe to mild) and the M-IASI (moderate to clear) after 12 weeks of QRX003 application is very encouraging. We fully support the investigator’s decision to continue treatment. In addition, the validated CDQLI questionnaire results to date indicate that the pediatric subject in the study is experiencing a distinct positive improvement in their quality of life as a result of ongoing treatment with QRX003. Consistent with what we are observing in our Netherton Syndrome studies, QRX003 is well tolerated with no adverse events reported. We look forward to expanding this study to include additional pediatric subjects in other countries and to advancing the clinical development of the product for this disease. There is currently no approved treatment or cure for peeling skin syndrome and there are no clinical studies listed on clinicaltrials.gov as actively recruiting and dosing subjects, thus presenting a further opportunity for Quoin to potentially achieve the first regulatory approval for another rare genetic disease. We are also continuing to advance QRX003 in our late-stage Netherton Syndrome clinical studies.”

  • Significant Improvement in Skin Appearance Noted After 12 Weeks Compared to Baseline
  • Key Metrics, Including Investigator’s Global Assessment (IGA), Modified Ichthyosis Area Severity Index (M-IASI), and Children’s Dermatology Life Quality Index (CDLQI), Show Positive Changes
  • Patient to Continue QRX003 Treatment for Further Evaluation
  • Quoin Advances QRX003 in Late-Stage Netherton Syndrome Trials

After 12 weeks of QRX003 treatment, the patient showed clear skin healing compared to baseline, as detailed below:

M-IASI: Modified Ichthyosis Area Severity Index, measuring skin symptom severity and extent. Lower scores indicate improvement.

QRX003 has been well tolerated, with no adverse events reported. Based on these positive results, the patient will continue treatment, with a follow-up assessment planned after 24 weeks.

Peeling Skin Syndrome (PSS) is a rare genetic disorder caused by corneodesmosin gene (CDSN) mutations, leading to excessive epidermal shedding. Patients experience severe pain and chronic itching. No approved treatments exist, and symptoms are typically managed with over-the-counter emollients.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (QNRX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.